Document Detail


Tissue factor pathway inhibitor and antithrombin trial results.
MedLine Citation:
PMID:  15992666     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The endogenous plasma anticoagulant proteins tissue factor pathway inhibitor (TFPI) and antithrombin (AT) have both been extensively studied in large, multinational phase III clinical trials in patients with severe sepsis. The TFPI and AT trials failed to result in significant reductions in the 28-day, all-cause mortality rates in their respective study populations. However, there appear to be definable patient populations within each study that may have benefited from TFPI or AT. Drug-drug interactions and dosing issues were observed in both trials. The similarities and differences of each anticoagulant and the lessons learned from the recent phase III clinical trials are examined in this review.
Authors:
Steven P LaRosa; Steven M Opal
Related Documents :
24222656 - New drug therapies interfering with the renin-angiotensin-aldosterone system for resist...
23960746 - Preparation of a novel floating ring capsule-type dosage form for stomach specific deli...
17050456 - The debate: a case for randomized controls in invasive aspergillosis.
20730696 - The utility of cardiovascular drugs in the treatment of cerebrovascular disease.
18771856 - In vitro evaluation of the growth inhibitory activities of 15 drugs against babesia gib...
11956676 - Knowledge on drug dosages of ward physicians.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Critical care clinics     Volume:  21     ISSN:  0749-0704     ISO Abbreviation:  Crit Care Clin     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-04     Completed Date:  2005-08-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8507720     Medline TA:  Crit Care Clin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  433-48     Citation Subset:  IM    
Affiliation:
Infectious Disease Division, Rhode Island Hospital, Gerry House 113, 593 Eddy Street, Providence, RI 02903, USA. slarosa@lifespan.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticoagulants / therapeutic use*
Double-Blind Method
Fibrinolytic Agents / therapeutic use*
Heparin / therapeutic use*
Humans
Lipoproteins / therapeutic use*
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Sepsis / drug therapy*,  mortality
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Lipoproteins; 0/lipoprotein-associated coagulation inhibitor; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sepsis and coagulation.
Next Document:  Disseminated intravascular coagulation: What's new?